OBI Pharma (ROCO:4174) Forward Dividend Yield %: 0.00% (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4174 OBI Pharma Inc ROCO:4174
43 GF Score
Price NT$28.40
GF Value NT$138.61
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is OBI Pharma Forward Dividend Yield %?

OBI Pharma ROCO:4174 -1.90% 43 Forward Dividend Yield % is 0.00% as of Jul. 15, 2026. GuruFocus rates ROCO:4174 with a GF Score™ of 43/100 and a GF Value™ of NT$138.61 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 149 Biotechnology companies, OBI Pharma ranks worse than 671140.27% on this metric.

As of today (2026-07-15), the Forward Annual Dividend Yield of OBI Pharma is 0.00%.

As of today (2026-07-15), the Trailing Annual Dividend Yield of OBI Pharma is 0.00%.

ROCO:4174's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.32
* Ranked among companies with meaningful Forward Dividend Yield % only.

OBI Pharma's Dividends per Share for the three months ended in Dec. 2025 was NT$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

OBI Pharma  (ROCO:4174) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

OBI Pharma Forward Dividend Yield % Related Terms

ROCO:4174 vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, OBI Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OBI Pharma Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where OBI Pharma's Forward Dividend Yield % falls into.


ROCO:4174
43GF Score
OBI Pharma Inc ROCO:4174
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OBI Pharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
OBI Pharma (ROCO:4174) has a Forward Dividend Yield % of 0.00% as of Jul. 15, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on OBI Pharma and its competitors. According to the industry distribution chart, OBI Pharma ranks #999999 out of 149 companies in the Biotechnology industry.
Is OBI Pharma's Forward Dividend Yield % too high?
OBI Pharma's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, OBI Pharma ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OBI Pharma has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OBI Pharma ranks #999999 out of 149 companies for Forward Dividend Yield %. This places OBI Pharma in the lower half of its industry. The industry median Forward Dividend Yield % is 1.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.32, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on OBI Pharma and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OBI Pharma's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
Based on GuruFocus' analysis, OBI Pharma (ROCO:4174) is currently considered Possible Value Trap. The stock's GF Value™ is NT$138.61, compared to a current price of NT$28.40 — trading 79.5% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. OBI Pharma's overall GF Score™ is 43/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current Forward Dividend Yield % is 0.00% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OBI Pharma (ROCO:4174) Overvalued in 2026?

Based on GuruFocus' analysis, OBI Pharma stock appears to be undervalued. The current stock price of NT$28.40 is trading 79.5% below its estimated GF Value™ of NT$138.61. GuruFocus considers OBI Pharma to be Possible Value Trap.

Key valuation signals for ROCO:4174:

  • Forward Dividend Yield %: 0.00%
  • GF Value™: NT$138.61 vs. price of NT$28.40 (79.5% below fair value)
  • GF Score™: 43/100 with 9 warning signs

No single metric tells the full story. See the ROCO:4174 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OBI Pharma Business Description

Address Zhongxiao East Road, 6th Floor, No. 508, Section 7, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
43GF Score

Get the complete analysis for ROCO:4174

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$28.40
Price
NT$138.61
GF Value